Quantcast

Latest Clinical trial Stories

2014-08-11 23:04:30

New partnership will give better clinical trial access and information to over 100,000 patient influencers. Boston and London (PRWEB) August 11, 2014 TrialReach, the world’s largest provider of clinical research information and patient-clinical trial matching, today announced a new collaboration with WEGO Health, a social network comprised of over 100,000 patient influencers. WEGO Health will expand its TrialShare platform by incorporating TrialReach tools and resources directly so that...

2014-08-11 16:25:35

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Spasticity Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2280943/Spasticity-Global-Clinical-Trials-Review-H2-2014.htmlSpasticity Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Spasticity Global Clinical Trials Review, H2, 2014" provides data on the Spasticity clinical trial scenario. This report provides elemental information and...

2014-08-11 16:25:30

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2280941/Spastic-Cerebral-Palsy-Global-Clinical-Trials-Review-H2-2014.htmlSpastic Cerebral Palsy Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Spastic Cerebral Palsy Global Clinical Trials Review, H2, 2014" provides data on the Spastic Cerebral Palsy clinical...

2014-08-11 16:25:21

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Pain Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/703965/Renal-Pain-Global-Clinical-Trials-Review-H2-2014.htmlRenal Pain Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Renal Pain Global Clinical Trials Review, H2, 2014" provides data on the Renal Pain clinical trial scenario. This report provides elemental information and...

2014-08-11 08:29:18

Trial Progressing On Track; BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced an update about the Company's Phase III clinical trial of DCVax®-L for Glioblastoma multiforme (GBM) brain cancer in conjunction with the Company's separate announcement today about certain changes to the Phase III trial. The update from the Company...

2014-08-11 08:28:51

With CE mark in place and FDA-directed studies underway in US, company accelerates market development efforts in US, Canada, Israel, and multiple countries in Europe ENGLEWOOD, Colo., Aug. 11, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis Diagnostics has expanded its academic and pharmaceutical research network to over 25 sites around the world. To date the company has initiated over 17 scientific and clinical research...

2014-08-08 08:25:48

THE WOODLANDS, Texas, Aug. 8, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 10:55 AM EDT in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived...

2014-08-07 16:29:04

CUPERTINO, Calif., Aug. 7, 2014 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the second quarter of 2014. Total revenues were $4.6 million and net loss was $5.5 million for the three months ended June 30, 2014 as compared to total revenues of $3.9 million and net loss of $5.1 million for the three months ended June 30, 2013. http://photos.prnewswire.com/prnvar/20020717/DRRXLOGO At June 30, 2014, we had cash and investments of $37.3 million, compared...

2014-08-07 16:28:49

SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "Trovagene is continuing to demonstrate the benefits of our precision cancer monitoring platform and is progressing toward our commercial roll-out later this year," said Antonius Schuh, Ph.D., chief executive officer of...

2014-08-07 16:28:19

Conference call to be held on Thursday, August 7, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced second quarter 2014 financial results. Clinical Developments and Anticipated Milestones -- Apatorsen -- The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types,...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'